Dai K, Wu Y, She S, Zhang Q. Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma. World J Gastrointest Oncol 2021; 13(12): 2029-2037 [PMID: 35070039 DOI: 10.4251/wjgo.v13.i12.2029]
Corresponding Author of This Article
Kai Dai, MD, PhD, Doctor, Department of Infectious Diseases, Renmin Hospital of Wuhan University, No. 238 Jiefang Road, Wuchang District, Wuhan 430060, Hubei Province, China. daikai@whu.edu.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Dec 15, 2021; 13(12): 2029-2037 Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2029
Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma
Kai Dai, Yin Wu, Sha She, Qian Zhang
Kai Dai, Yin Wu, Sha She, Qian Zhang, Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China
Author contributions: Dai K performed the majority of the writing and prepared the table; Wu Y, She S and Zhang Q carried out the literature review for data collection, and coordinated the writing of the paper; all authors have read and approve the final manuscript.
Supported byThe National Natural Science Foundation of China, No. 81972673.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kai Dai, MD, PhD, Doctor, Department of Infectious Diseases, Renmin Hospital of Wuhan University, No. 238 Jiefang Road, Wuchang District, Wuhan 430060, Hubei Province, China. daikai@whu.edu.cn
Received: February 20, 2021 Peer-review started: February 20, 2021 First decision: July 29, 2021 Revised: August 4, 2021 Accepted: October 27, 2021 Article in press: October 27, 2021 Published online: December 15, 2021 Processing time: 297 Days and 10.2 Hours
Abstract
With the advance of genome engineering technology, chimeric antigen receptors (CARs)-based immunotherapy has become an emerging therapeutic strategy for tumors. Although initially designed for T cells in tumor immunotherapy, CARs have been exploited to modify the function of natural killer (NK) cells against a variety of tumors, including hepatocellular carcinoma (HCC). CAR-NK cells have the potential to sufficiently kill tumor antigen-expressing HCC cells, independent of major histocompatibility complex matching or prior priming. In this review, we summarize the recent advances in genetic engineering of CAR-NK cells against HCC and discuss the current challenges and prospects of CAR-NK cells as a revolutionary cellular immunotherapy against HCC.
Core Tip: Chimeric antigen receptors (CARs)-based immunotherapy is an emerging therapeutic strategy for tumors. This review summarizes the recent advances in genetic engineering of CAR-natural killer (NK) cells against hepatocellular carcinoma and discuss the current challenges and prospects of CAR-NK cells as a revolutionary cellular immunotherapy against hepatocellular carcinoma.
